Cisplatin otoprotection using transtympanic L-N-acetylcysteine: A pilot randomized study in head and neck cancer patients

Laryngoscope

Volumn 124, Issue 3, 2014, Pages

  Yoo, John ^a   Hamilton, Scott J ^c   Angel, Douglas ^a   Fung, Kevin ^a   Franklin, Jason ^c   Parnes, Lorne S ^a   Lewis, Denise ^b   Venkatesan, Varagur ^a   Winquist, Eric ^a  

^a WESTERN UNIVERSITY   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Cisplatin; L N Acetylcysteine; otoprotection; ototoxicity; transtympanic

Indexed keywords

CISPLATIN; L-N-ACETYLCYSTEINE; OTOPROTECTION; OTOTOXICITY; TRANSTYMPANIC;

ACETYLCYSTEINE; ADULT; AUDIOMETRY; AUDITORY THRESHOLD; CISPLATIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEARING LOSS, SENSORINEURAL; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; TREATMENT OUTCOME; TYMPANIC MEMBRANE;

EID: 84894477345     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24360     Document Type: Conference Paper

References (55)

1. Blumenreich MS, Woodcock TM, Jones M, et al. High-dose cisplatin in patients with advanced malignancies. Cancer 1985; 55: 1118-1122.
2. Adelstein DJ,. Concurrent chemoradiotherapy in the management of squamous cell cancer of the oropharynx: current standards and future directions. Int J Radiat Oncol Biol Phys 2007; 69 (suppl 2): S37-39.
3. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
4. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
5. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-1944.
6. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-1952.
7. Pignon JP, Bourhis J, Domenge C, et al. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
8. Choe WT, Chinosornvatana N, Chang KW,. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004; 25: 910-915.
9. Moroso MJ, Blair RL,. A review of cis-platinum ototoxicity. J Otolaryngol 1983; 12: 365-369.
10. Weatherly RA, Owens JJ, Catlin FI, et al. Cis-platinum ototoxicity in children. Laryngoscope 1991; 101: 917-924.
11. Roland PS, Rutka JA,. Ototoxicity. Hamilton, Ontario: BC Decker Inc; 2004.
12. Feghali JG, Liu W, Van De Water TR,. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 2001; 111: 1147-1155.
13. Schweitzer VG,. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 1993; 103: 1-52. Review.
14. Hinojosa R, Riggs LC, Strauss M, et al. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 1995; 16: 731-740.
15. Anniko M, Sobin A,. Cisplatin: evaluation of its ototoxic potential. Am J Otolaryngol 1986; 7: 276-293.
16. Tange RA, Vuzevski VD,. Changes in the stria vascularis of the guinea pig due to cis-platinum. Arch Otorhinolaryngol 1984; 239: 41-47.
17. Kopke RD, Liu W, Gabaizadeh R, et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 1997; 18: 559-571.
18. Rybak LP,. Cis-platinum associated hearing loss. J Laryngol Otol 1981; 95: 745-747.
19. Stocks RM, Gould HJ, Bush AJ, et al. Ototoxic protection of sodium thiosulfate: daily vs. constant infusion. Otolaryngol Head Neck Surg 2004; 131: 115-119.
20. Gandara DR, Wiebe VJ, Perez EA, et al. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 1990; 10: 353-365.
21. Dickey DT, Wu YJ, Muldoon LL, et al. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 2005; 314: 1052-1058.
22. Dickey TD, Muldoon LL, Kraemer DF, et al. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 2004; 193: 25-30.
23. Boheim K, Bichler E,. Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol 1985; 242: 1-6.
24. Saito T, Yamada T, Manabe Y, et al. Cisplatin metabolites and their toxicity on isolated cochlear outer hair cells in vitro. Acta Otolaryngol 1996; 116: 561-565.
25. Clerici WJ, Hensley K, DiMartino DL, et al. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res 1996; 98: 116-124.
26. Ravi R, Somani SM, Rybak LP,. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol 1995; 76: 386-394.
27. Rybak LP, Whitworth C, Somani S,. Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope 1999; 109: 1740-1744.
28. Rybak LP, Husain K, Morris C, et al. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000; 21: 513-520.
29. Teranishi M, Nakashima T, Wakabayashi T,. Effects of alpha-tocopherol on cisplatin-induced ototoxicity in guinea pigs. Hear Res 2001; 151: 61-70.
30. Zheng JL, Gao WQ,. Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures. Eur J Neurosci 1996; 8: 1897-1905.
31. Wang J, Lloyd Faulconbridge RV, Fetoni A, et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology 2003; 45: 380-393.
32. Kaltenbach JA, Church MW, Blakley BW, et al. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg 1997; 117: 493-500.
33. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001; 7: 493-500.
34. Kamimura T, Whitworth CA, Rybak LP,. Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hear Res 1999; 131: 117-127.
35. Boogaard PJ, Lempers EL, Mulders GJ, et al. 4-Methylthiobenzoic acid reduces cisplatin nephrotoxicity in rats without compromising anti-tumour activity. Biochem Pharmacol 1991; 41: 1997-2003.
36. Campbell KC, Rybak LP, Meech RP, et al. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 1996; 102: 90-98.
37. Campbell KC, Meech RP, Rybak LP, et al. D-Methionine protects against cisplatin damage to the stria vascularis. Hear Res 1999; 138: 13-28.
38. Cloven NG, Re A, McHale MT, et al. Evaluation of D-methionine as a cytoprotectant in cisplatin treatment of an animal model for ovarian cancer. Anticancer Res 2000; 20: 4205-4209.
39. Reser D, Rho M, Dewan D, et al. L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology 1999; 20: 731-748.
40. Wimmer C, Mees K, Stumpf P, et al. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 2004; 25: 33-40.
41. Li G, Frenz DA, Brahmblatt S, et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 2001; 22: 163-176.
42. Korver KD, Rybak LP, Whitworth C, et al. Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 2002; 126: 683-689.
43. Holdiness MR,. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 1991; 20: 123-134.
44. Rumack BH, Bateman DN,. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila). 2012 Feb; 50 (2): 91-8. Review.
45. Klein-Schwartz W, Doyon S,. Intravenous acetylcysteine for the treatment of acetaminophen overdose. Expert Opin Pharmacother 2011; 12: 119-130. Epub 2010. Review.
46. Duijvestijn YC, Mourdi N, Smucny J, et al. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev 2009;(1): CD003124. doi: 10.1002/14651858.CD003124.pub3. Review.
47. Messner K, Leibowitz HM,. Acetylcysteine treatment of keratitis sicca. Arch Ophthalmol 1971; 86: 357-359.
48. Lopez-Gonzalez MA, Guerrero JM, Rojas F, et al. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res 2000; 28: 73-80.
49. Konstantinov S, Topashka-Ancheva M, Karaivanova M, et al. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC. Neoplasma 1994; 41: 253-258.
50. Rauch SD, Halpin CF, Antonelli PJ, et al. Oral vs. intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011; 305: 2071-2079.
51. Hu A, Parnes LS,. Intratympanic steroids for inner ear disorders: a review. Audiol Neurootol 2009; 14: 373-382. Epub 2009. Review.
52. Nedzelski JM, Chiong CM, Fradet G, et al. Intratympanic gentamicin instillation as treatment of unilateral Meniere's disease: update of an ongoing study. Am J Otol 1993; 14: 278-282.
53. Lachin JM,. Introduction to sample size determination and power analysis for clinical trials. Controlled Clinical Trials 1981; 2: 93-113.
54. Riga MG, Chelis L, Kakolyris S, et al. Transtympanic Injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy. Am J Clin Oncol 2013; 36: 1-6. doi: 10.1097/COC.0b013e31822e006d.
55. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 1355-1362.